| Product Unit Size | Cost | Quantity | Stock |
|---|
Omeprazole is a proton pump inhibitor (PPI) that acts as an antagonist at H+/K+ ATPases and is clinically used to treat gastroesophageal reflux disease (GERD), dyspepsia, and peptic ulcer disease. Omeprazole Related Compound E is an impurity that may be formed during the synthesis or degradation of omeprazole.
Omeprazole N-oxide is an impurity of omeprazole.
| Cas No. | 176219-04-8 |
|---|---|
| Purity | ≥98% |
| Formula | C17H19N3O4S |
| Formula Wt. | 361.42 |
| Chemical Name | 6-Methoxy-2-[[(4-methoxy-3,5-dimethyl-1-oxido-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole |
| IUPAC Name | 6-methoxy-2-[(4-methoxy-3,5-dimethyl-1-oxidopyridin-1-ium-2-yl)methylsulfinyl]-1H-benzimidazole |
| Synonym | Omeprazole N-oxide; 4-Methoxy-2-(((5-methoxy-1H-benzo[d]imidazol-2-yl)sulfinyl)methyl)-3,5-dimethylpyridine 1-oxide |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Tonazzi A, Eberini I, Indiveri C. Molecular mechanism of inhibition of the mitochondrial carnitine/acylcarnitine transporter by omeprazole revealed by proteoliposome assay, mutagenesis and bioinformatics. PLoS One. 2013 Dec 9;8(12):e82286. PMID: 24349247.
Ward RM, Kearns GL. Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs. 2013 Apr;15(2):119-31. PMID: 23512128.
Mefford IN, Mefford JT, Burris CA. Improved diabetes control and pancreatic function in a type 2 diabetic after omeprazole administration. Case Rep Endocrinol. 2012;2012:468609. PMID: 22937295.